Abbvie plans to lift $2 billion cap on deals - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
February 6, 2023 11:17 AM ESTAbbVie (NYSE: ABBV) is looking towards its new drugs to replace Humiria now that its blockbuster immune-disease therapy is facing lower-priced competition, the Wall Street Journal said Monday.
The WSJ said that the drugmaker's Chief Executive, Richard Gonzalez, revealed the company is turning to a pair of next-generation successors to reload the billions of dollars in sales that will be lost.
In... More
